充剂收入$11.4million、同比增5.7%;当期毛利率65.4%同比降620bps,净亏损$7.4million、摊薄后每股亏损$0.23,期末现金余额$11.2million。全年业绩指引大幅下修至预计全年营收>$175million、调整后EBITDA>$25million,核心归因于上半年召回延续